Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair-associated gene alterations in solid tumors from a large Asian cohort.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) is associated with sensitivity to platinum-based chemotherapy and PARP inhibitors in BRCA-associated cancers, including ovarian, breast, prostate, and pancreatic cancers. This study explores HRD and homologous recombination repair (HRR) gene alterations in a pan-cancer cohort to guide precision oncology.

Methods

Clinical and genomic data from 9,262 patients with 17 solid tumor types were analyzed using the OncoScreen^TM Plus kit. HRD scores, biallelic HRR and tumor suppressor gene alterations, and their clinical correlations were evaluated.

Results

HRD scores varied across cancer types, all showing a long tail in distribution. The prevalence of pathogenic alterations in pan-cancer HRR was 21.3%, with 13.7%

SUBMITTER: Ren L 

PROVIDER: S-EPMC12107993 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature